VYNE Therapeutics VYNE Stock
VYNE Therapeutics Price Chart
VYNE Therapeutics VYNE Financial and Trading Overview
| VYNE Therapeutics stock price | 28.56 USD |
| Previous Close | 0 USD |
| Open | 25.5 USD |
| Bid | 20.35 USD x 200 |
| Ask | 31.36 USD x 200 |
| Day's Range | 23.37 - 28.56 USD |
| 52 Week Range | 14.03 - 46.95 USD |
| Volume | 93.26K USD |
| Avg. Volume | 17.63K USD |
| Market Cap | 19.07M USD |
| Beta (5Y Monthly) | 2.006 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -27.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | July 22, 2026 |
| 1y Target Est | N/A |
VYNE Valuation Measures
| Enterprise Value | -5876852 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.3461818 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 42.00339 |
| Price/Book (mrq) | 0.77327126 |
| Enterprise Value/Revenue | -12.945 |
| Enterprise Value/EBITDA | 0.241 |
Trading Information
VYNE Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.006 |
| 52-Week Change | 52.63% |
| S&P500 52-Week Change | 18.95% |
| 52 Week High | 46.95 USD |
| 52 Week Low | 14.03 USD |
| 50-Day Moving Average | 34.03 USD |
| 200-Day Moving Average | 28.6 USD |
VYNE Share Statistics
| Avg. Volume (3 month) | 17.63K USD |
| Avg. Daily Volume (10-Days) | 47.29K USD |
| Shares Outstanding | 667.7K |
| Float | 613.69K |
| Short Ratio | 0.15 |
| % Held by Insiders | 17.93% |
| % Held by Institutions | 39.61% |
| Shares Short | 3.68K |
| Short % of Float | 0.55% |
| Short % of Shares Outstanding | 0.54% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4437.20% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.012% |
| Return on Equity (ttm) | -63.16% |
Income Statement
| Revenue (ttm) | 454K USD |
| Revenue Per Share (ttm) | 0.53 USD |
| Quarterly Revenue Growth (yoy) | -57.39% |
| Gross Profit (ttm) | 454K USD |
| EBITDA | -24345000 USD |
| Net Income Avi to Common (ttm) | -21718000 USD |
| Diluted EPS (ttm) | -27.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 24.93M USD |
| Total Cash Per Share (mrq) | 37.37 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 20.865 |
| Book Value Per Share (mrq) | 36.934 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25744000 USD |
| Levered Free Cash Flow (ttm) | -20400000 USD |
Profile of VYNE Therapeutics
| Country | United States |
| State | NJ |
| City | Stewartsville |
| Address | P.O. BOX 125 |
| ZIP | 08886 |
| Phone | 800 775 7936 |
| Website | https://vynetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Q&A For VYNE Therapeutics Stock
What is a current VYNE stock price?
VYNE Therapeutics VYNE stock price today per share is 28.56 USD.
How to purchase VYNE Therapeutics stock?
You can buy VYNE shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for VYNE Therapeutics?
The stock symbol or ticker of VYNE Therapeutics is VYNE.
Which industry does the VYNE Therapeutics company belong to?
The VYNE Therapeutics industry is Biotechnology.
How many shares does VYNE Therapeutics have in circulation?
The max supply of VYNE Therapeutics shares is 667.7K.
What is VYNE Therapeutics Price to Earnings Ratio (PE Ratio)?
VYNE Therapeutics PE Ratio is now.
What was VYNE Therapeutics earnings per share over the trailing 12 months (TTM)?
VYNE Therapeutics EPS is -27.58 USD over the trailing 12 months.
Which sector does the VYNE Therapeutics company belong to?
The VYNE Therapeutics sector is Healthcare.
VYNE Therapeutics VYNE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26690.62 USD — |
+1.3
|
7.21B USD — | 26478.01 USD — | 26712.62 USD — | — - | 7.21B USD — |
|
US Tech Health Care
IXHC
US
|
1293.16 USD — |
+2.08
|
— — | 1273.79 USD — | 1294.2 USD — | — - | — — |
- {{ link.label }} {{link}}
